Zacks Investment Research on MSN22h
Here's Why You Should Retain Glaukos Stock in Your PortfolioGlaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product ...
The firm says its “bullish” key opinion leader checks indicated the “disruptive potential” of iDose across the U.S. glaucoma treatment landscape over the next several years. The checks ...
Zacks Investment Research on MSN13d
GKOS Crashes Almost 25% After Q4 Earnings: How to Play the Stock?Glaukos Corporation GKOS reported record fourth-quarter 2024 revenues of $105.5 million, reflecting a 28% year-over-year ...
The firm notes Glaukos reported Q4 sales above consensus, driven by iDose and OUS MIGS, offsetting weaker core U.S. MIGS due to LCD headwinds. 2025 sales guidance brackets the Street, with iDose ...
Strong growth in the US glaucoma franchise with record fourth-quarter net sales of $56.3 million, driven by the success of iDose TR. The company faces potential headwinds from foreign currency ...
Key products include the iStent and iStent inject W micro-bypass stents for treating open-angle glaucoma and the iDose TR, an intracameral implant that delivers glaucoma medication for up to three ...
Local medical device companies last month posted fourth quarter results that exceeded analysts’ expectations.Irvine’s Masimo ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback